Assessment of PTeye™ versus FLUOBEAM® LX for parathyroid adenomas: a pilot case–control study - Takeaways - MDSpire

Assessment of PTeye™ versus FLUOBEAM® LX for parathyroid adenomas: a pilot case–control study

  • By

  • Theodosios Papavramidis

  • Angeliki Chorti

  • Sohail Bakkar

  • July 29, 2025

  • 0 min

Share

  • 1

    Parathyroid adenoma is the leading cause of primary hyperparathyroidism, necessitating effective identification methods during parathyroidectomy.

  • 2

    This study compares the efficacy of PTeye™ and FLUOBEAM® LX in identifying parathyroid adenomas during surgery.

  • 3

    PTeye™ successfully identified all parathyroid adenomas (100%), while FLUOBEAM® LX missed 15% of cases.

  • 4

    PTeye™ demonstrated faster identification times, confirming parathyroid tissue in under 1 minute for 65% of cases.

  • 5

    The study supports the use of near-infrared autofluorescence technology as a valuable tool for parathyroid adenoma identification.

Original Source(s)

Assessment of PTeye™ versus FLUOBEAM® LX for parathyroid adenomas: a pilot case–control study

  • by Theodosios Papavramidis, Angeliki Chorti, Sohail Bakkar

  • July 29, 2025

Related Content

Transmural cross-sectional findings and bowel damage assessment in preclinical Crohn’s disease: a case-control study

Volumes and velocities: Meta-analysis of PC-MRI studies in normal pressure hydrocephalus

Impact and effect of imaging referral guidelines on patients and radiology services: a systematic review